5 FDA Decisions to Watch in the First Quarter of 2026

Why It Matters

Accelerated approvals could shift competitive advantage, unlock multi‑billion‑dollar markets, and provide critical funding mechanisms for biotech firms.

Key Takeaways

• Orforglipron gets national‑priority voucher, could beat oral Wegovy
• Bitopertin targets rare erythropoietic protoporphyria, FDA review accelerated
• TransCon CNP weekly injection may challenge Voxzogo monopoly
• Imcivree shows 20% weight loss in hypothalamic obesity
• Kresladi could earn nine‑figure voucher, boost Rocket's pipeline

Pulse Analysis

The FDA’s national‑priority voucher program is becoming a strategic lever for pharmaceutical giants. By slashing review timelines to as little as one to two months, the program enables companies like Eli Lilly to bring cost‑effective, small‑molecule oral GLP‑1 therapies to market faster than peptide‑based competitors. This not only narrows the first‑mover advantage enjoyed by Novo Nordisk’s oral Wegovy but also promises lower manufacturing costs, potentially reshaping pricing dynamics in the rapidly expanding obesity market, which analysts forecast could exceed $30 billion globally within the next decade.

For rare‑disease developers, expedited pathways are equally transformative. Disc Medicine’s bitopertin, repurposed from a failed schizophrenia trial, now targets erythropoietic protoporphyria—a condition with no approved therapy—while Ascendis’s TransCon CNP aims to dethrone BioMarin’s Voxzogo in achondroplasia. Both drugs benefit from the FDA’s “large unmet medical need” criteria, granting them priority review and, in some cases, voucher eligibility. These mechanisms not only accelerate patient access but also create valuable secondary markets for vouchers, influencing merger‑and‑acquisition strategies and patent litigation tactics across the biotech sector.

Gene‑therapy firms are watching the same regulatory momentum with keen interest. Rocket Pharma’s Kresladi, a potential treatment for severe leukocyte adhesion deficiency‑I, could secure a priority‑review voucher worth nine figures, providing a cash infusion that may fund its broader pipeline, including a cardiovascular program for Danon disease. The prospect of such high‑value vouchers underscores a broader industry shift: regulatory speed can translate directly into financial runway, enabling smaller biotechs to compete with entrenched players and investors to reassess risk‑return profiles in light of faster path‑to‑market timelines. This regulatory acceleration is poised to redefine capital allocation and competitive strategy across multiple therapeutic areas.